Ongoing Clinical Validation: Randomized Controlled Trial for Chatdok-Heart
Demostrating our commitment to evidence-based AI, we are conducting a multicenter, randomized, controlled, single-blinded trial to evaluate the real-world impact of Chatdok-Heart in chronic cardiovascular care.
The primary objective is to determine the effectiveness of Chatdok-Heart’s AI-assisted platform in reducing cardiovascular events including myocardial infarction, stroke, and heart failure hospitalizations,
and improving key risk factors such as blood pressure and cholesterol. This study represents a critical step in validating AI-driven digital therapeutics for proactive, evidence-based heart failure management.